Published date: Oct 09 2024

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 22, Issue No. 8

Pages: 651–660

DOI: 10.18502/ijrm.v22i8.17238

Hamideh GholamiDepartment of Oncology, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.

Lida GarrosiDepartment of Obstetrics and Gynecology, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.

Shabnam TofighiDepartment of Obstetrics and Gynecology, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.

Zahra Ghadimizahraghadimi@zums.ac.irDepartment of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran.

Background: Although an optimal screening model is still under investigation, pre-eclampsia is a leading cause of perinatal morbidity. The association between cancer-antigen-125 (CA-125) and pre-eclampsia has been discussed in several studies recently.

Objective: We aimed to determine the association between CA-125 and preeclampsia and estimated fetal weight.

Materials and Methods: This case-control study was performed on 30 pregnant women with pre-eclampsia who were homogenized in terms of age, body mass index, and gestational age with 30 normal pregnant women. Participants were recruited via convenience sampling. The level of CA-125 in blood at the time of termination of pregnancy was measured by Enzyme Linked Immunosorbent Assay. The urine sample was used to check proteinuria. Blood pressure and pregnancy outcomes were assessed and recorded. 

Results: The mean serum CA-125 level in study group was considerably higher than control group (p < 0.001). Elevating the level of CA-125 has increased the likelihood of pre-eclampsia by 1.5 times. A significant direct correlation was obtained between CA-125 level and the amount of urinary protein (r = 0.605, p < 0.001). Also, a significant but negative correlation was obtained between the CA-125 level and the estimated weight of the fetus (r = -0.593, p < 0.001).

Conclusion: Increasing the serum level of CA-125 with high sensitivity and specificity is significantly associated with the occurrence of pre-eclampsia and estimated fetal weight.

Key words: CA-125, Pre-eclampsia, Birth weight.

[1] Gholami H, Fayazi S, Shirshekan M, Motamed N, Tofighi S. Comparison of serum level of vitamin D in pregnant women with preeclampsia and a control group in Ayatollah Mousavi hospital in Zanjan. J Obstet Gynecol Cancer Res 2022; 7: 335–340.

[2] Wiles K, Chappell LC, Lightstone L, Bramham K. Updates in diagnosis and management of preeclampsia in women with CKD. Clin J Am Soc Nephrol 2020; 15: 1371–1380.

[3] Lim S, Li W, Kemper J, Nguyen A, Mol BW, Reddy M. Biomarkers and the prediction of adverse outcomes in pre-eclampsia: A systematic review and meta-analysis. Obstet Gynecol 2021; 137: 72–81.

[4] Hossain AT, Siddique AB, Jabeen S, Khan Sh, Haider M, Ameen Sh, et al. Maternal mortality in Bangladesh: Who, when, why, and where? A national survey-based analysis. J Glob Health 2023; 13: 07002.

[5] Chan JK, Tian Ch, Kesterson JP, Richardson MT, Lin K, Tewari KS, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecol Oncol 2022; 167: 429–435.

[6] Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS, International Collaboration to Harmonise Outcomes and Measures for Endometriosis. Diagnostic accuracy of cancer antigen 125 for endometriosis: A systematic review and meta-analysis. BJOG 2016; 123: 1761-1768.

[7] Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Hypertension in pregnancy. Obstet Gynecol 2013; 122: 1122–1131.

[8] Patil MB, Lavanya T, Kumari CM, Shetty ShR, Gufran Kh, Viswanath V, et al. Serum ceruloplasmin as cancer marker in oral pre-cancers and cancers. J Carcinog 2021; 20: 15.

[9] Sanford BH, Labbad G, Hersh AR, Heshmat A, Hasley S. Leveraging American College of Obstetricians and Gynecologists guidelines for point-of-care decision support in obstetrics. Appl Clin Inform 2021; 12: 800–807.

[10] Macdonald-Wallis C, Lawlor DA, Heron J, Fraser A, Nelson SM, Tilling K. Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy. PLoS One 2011; 6: e22115.

[11] Aremu-Kasumu YB, Nwobodo EI, Ango IG, Abdulrahman MB, Fatusin AJ, Fatusin BB. Association between preeclampsia and cancer antigen 125 in women attending antenatal clinic in Usmanu, Danfodiyo University Teaching Hospital, Sokoto. Trop J Obstet Gynaecol 2020; 37: 53–57.

[12] Barooti E, Rashidi Fakari F, Darvish S, Tavakoly N. The comparison of CA-125 levels in the normal pregnancy and threatened abortion. J Obstet Gynecol Cancer Res 2022; 7: 226–229.

[13] Balint O, Secosan C, Pirtea L. Role of CA-125 level as a marker in the management of severe pre-eclampsia. Healthcare 2022; 10: 2474.

[14] Karaman E, Karaman Y, Alkis I, Han A, Yildirim G, Ark HC. Maternal serum CA-125 level is elevated in severe preeclampsia. Pregnancy Hypertens 2014; 4: 29–33.

[15] Afshani N, Moustaqim-Barrette A, Biccard BM, Rodseth RN, Dyer RA. Utility of B-type natriuretic peptides in pre-eclampsia: A systematic review. Int J Obstet Anesth 2013; 22: 96-103.

[16] Gottipati G, Supriya K. Maternal serum cancer antigen 125: A marker of severity of pre-eclampsia. J South Asian Feder Obstet Gynaecol 2019; 11: 153–155.

[17] Szabo G, Molvarec A, Nagy B, Rigo Jr J. Increased B-type natriuretic peptide levels in early-onset versus late-onset pre-eclampsia. Clin Chem Lab Med 2014; 52: 281-288.

[18] Boroumand F, Ghasem Baglou S, Rasouli J, Vazifekhah S. The comparison of serum CA-125 levels in women with normal pregnancy and severe and non-severe preeclampsia. J Babol Univ Med Sci 2022; 24: 372–382.

[19] Bhatia P, Goel P, Mehra R, Dubey S, Gupta S. Correlation of serum cancer antigen-125 (CA-125) levels with severity of pre-eclampsia. J Obstet Gynecol India 2023; 73 (Suppl.): 240–246.

[20] Ibrahem WW, Al-Assaly RKh, Al-Haddad NS. CA-125, plasma fibrinogen and C-reactive protein in correlation with severity of pre-eclampsia. J Fac Med Baghdad 2017; 59: 31–35.

[21] Ozat M, Kanat-Pektas M, Yenicesu O, Gungor T, Danisman N, Mollamahmutoglu L. Serum concentrations of CA-125 in normal and preeclamptic pregnancies. Arch Gynecol Obstet 2011; 284: 607–612.

[22] Bellos I, Pergialiotis V, Loutradis D, Papapanagiotou A, Daskalakis G. Serum CA-125 levels in pre-eclampsia: A systematic review and meta-analysis. Int J Clin Pract 2019; 73: e13380.

[23] Balint O, Secosan C, Pirtea L. Assessment of CA-125 First-trimester values as a potential screening marker for pre-eclampsia. Medicina 2023; 59: 891.

[24] Tyler Ch, Kapur A, Felder M, Belisle JA, Trautman Ch, Gubbels JAA, et al. The mucin MUC16 (CA-125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and pre-eclampsia. Am J Reprod Immunol 2012; 68: 28–37.

[25] Schröcksnadel H, Daxenbichler G, Artner E, Steckel-Berger G, Dapunt O. Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest 1993; 35: 204–208.

[26] Bhattacharya A, Saha R. Serum concentrations of CA-125 in normal and preeclamptic pregnancies. IOSR J Pharm 2014; 4: 14–17.

[27] Mukherjee B, Das A. Association between serum Ca-125 levels and severity of pre-eclampsia: A case-control study conducted in a Tertiary Care Centre, West Bengal. Int J Reprod Contracept Obstet Gynecol 2020; 9: 4176.